<DOC>
	<DOC>NCT02023099</DOC>
	<brief_summary>This is a phase 3, double-blinded, multicenter study. The study will consist of 2 substudies: Substudy 1 (SS1) will be double-blinded and enroll non-cirrhotic subjects and Substudy 2 (SS2) will be open label and enroll subjects with compensated cirrhosis.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic HCVinfection prior to study enrollment Screening laboratory result indicating HCV subgenotype 1b infection Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening Voluntarily sign an informed consent Females must be practicing specific forms of birth control on study treatment, or be postmenopausal for more than 2 years or surgically sterile Coinfection of Hepatitis B Virus (HBV), human immunodeficiency virus (HIV) or any HCV genotype other than subgenotype 1b Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir, simeprevir and boceprevir Any cause of liver disease other than chronic HCVinfection, including but not limited to the following: hemochromatosis; alpha1 antitrypsin deficiency; Wilson's disease; autoimmune hepatitis; alcoholic liver disease; drugrelated liver disease; clinically significant laboratory abnormalities; uncontrolled clinically significant disease, disorder or medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Genotype 1b</keyword>
	<keyword>Cirrhotic</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>Japanese</keyword>
	<keyword>ombitasvir</keyword>
	<keyword>paritaprevir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>VIEKIRAX Combination Tablets</keyword>
</DOC>